Please use this identifier to cite or link to this item:
|Title:||Modulation of gene transcription by natural products - a viable anticancer strategy?|
Gescher, Andreas J.
|Publisher:||Bentham Science Publishers|
|Citation:||Current Pharmaceutical Design, 2007, 13 (27), pp. 2744-2750.|
|Abstract:||Drug design based on the structure of specific enzymes playing a role in carcinogenesis, e.g. tyrosine kinases, has been successful at identifying novel effective anticancer drugs. In contrast, no success has been achieved in drug design attempts, in which transcription factors or DNA-transcription factor complexes involved in the pathogenesis of human neoplasms were targeted. This failure is likely to be due to the fact that the mechanism of transcription regulation is probably too complex and still too inadequately understood to be a suitable target for drug design. It seems plausible that the high selectivity of some human tumors to some DNA-interactive anticancer drugs, e.g. cisplatin, is related to an effect on the transcription of genes that are crucial for those tumors. In this article we propose that some natural products have evolutionarily evolved to exert highly specialized functions, including modulation of the transcriptional regulation of specific genes. We discuss in detail the marine natural product Yondelis (Trabectedin, ET-743) that is effective against some soft tissue sarcoma, possibly because it interferes with the aberrant transcription mechanism in these tumors. In addition we highlight the existing evidence that many different natural products are effective inhibitors of NF-kB, a transcription factor that plays a crucial role in inflammation and cancer, indicating that some of these compounds might possess antitumor properties. We propose that large-scale characterization of natural products acting as potential modulators of gene transcription is a realistic and attractive approach to discover compounds therapeutically effective against neoplastic diseases characterized by specific aberrations of transcriptional regulation.|
|Rights:||This is the author's final draft of the paper published as Current Pharmaceutical Design, 2007, 13 (27), pp. 2744-2750. The final version is available from http://www.ingentaconnect.com. Doi: 10.2174/138161207781757097|
|Appears in Collections:||Published Articles, Dept. of Cancer Studies and Molecular Medicine|
Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.